Start the learning journey here

This Quality Improvement Activity enables you to review the glycaemic management of your type 2 diabetes patients and identify those who may benefit from initiation or intensification of blood glucose lowering medicines.

Good glycaemic control has a clear benefit on microvascular outcomes and if started early enough, on long-term macrovascular outcomes of coronary artery disease, stroke and peripheral vascular disease.

This is a Measuring and Improving Outcomes (MIO) activity that meets RNZCGP CPD requirements.

Diabetes clinical nurse specialist Lisa Sparks discusses the place of empagliflozin and dulaglutide in treatment of type 2 diabetes, with emphasis on potential side effects, sick-day management and improving patient adherence.

Māori attitudes to healthcare today are deeply rooted in New Zealand history. In this article, Deborah Bassett-Clarke discusses some reasons why the current model of pharmacy practice does not always meet the needs of Māori and may actually cause health inequities. Understanding these factors is an important first step to improving outcomes for Māori.

Medicine affordability is one of the five drivers of medicine access equity.

Up to 40 per cent of people continue to pay prescription copayments even though they are entitled to an exemption.¹ No person or family should pay more than $100 per annum for subsidised medicines.

Read the HAH bulletin to find out more. 

This list of Q&A reflects issues discussed in webinars held early in 2021.

The content has been edited, and reviewed by Waikato DHB endocrinologist/diabetologist Dr Ryan Paul.

Current management of type 2 diabetes includes two new classes of medication, SGLT2 inhibitors and GLP-1 receptor agonists, where clinically indicated. This article was published in the April 2021 edition of Kai Tiaki. It has been edited specifically for our nursing readership from an article that appeared in New Zealand Doctor and Pharmacy Today late in 2020. 

This article is endorsed by the College of Nurses Aotearoa (NZ) Inc.